John L. Dillon is a pharmaceutical process R&D professional with 37 years of experience in global leadership roles including a variety of executive positions at Bristol-Myers Squibb, Honeywell, Schering-Plough, Wyeth, Pfizer and, most recently, as CEO of Porton USA, a US subsidiary of Porton Pharma Solutions, a China-based CDMO (Contract Development and Manufacturing Organization). John served as the Vice President of New Products Process Development at Wyeth Pharmaceuticals where he was responsible for building a global group to develop and commercialize new products from the Wyeth Pipeline based on the principles of Quality by Design (QbD). After the acquisition of Wyeth by Pfizer, he served as the Vice President of API Technology leading a diverse group of process chemists, analysts and engineers responsible for second gen process development including use of chemical, engineering and enzyme technology for API production. John earned a B.S. (magna cum laude) from Syracuse University, and a Ph.D. in Organic Chemistry from SUNY Binghamton.

John is currently serving as adjunct faculty at Kean University in Union, New Jersey conducting research.